Pruritis - Pipeline Insight, 2022
Description
Pruritis - Pipeline Insight, 2022
DelveInsight’s, Pruritis - Pipeline Insight, 2022,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Pruritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Pruritis: Overview
Pruritus, or itching, is a frequent complaint heard by dermatologists and primary care physicians. Although generally considered a benign symptom, pruritus can have adverse effects on a patient’s wellbeing and can be incapacitating when severe. The mechanisms of pruritus are not particularly well understood and are compounded by the subjective nature of the process itself. Pruritus occurs with a host of dermatological conditions, but can also be a marker of systemic disease. Dermatologists and primary care physicians must be aware of the varied causes of itching.
""Pruritis - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pruritis pipeline landscape is provided which includes the disease overview and Pruritis treatment guidelines. The assessment part of the report embraces, in depth Pruritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pruritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
Pruritis Drugs
Further product details are provided in the report……..
Pruritis: Therapeutic Assessment
This segment of the report provides insights about the Pruritis drugs segregated based on following parameters that define the scope of the report, such as:
Pruritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pruritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pruritis drugs.
Pruritis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, Pruritis - Pipeline Insight, 2022,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Pruritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Pruritis: Overview
Pruritus, or itching, is a frequent complaint heard by dermatologists and primary care physicians. Although generally considered a benign symptom, pruritus can have adverse effects on a patient’s wellbeing and can be incapacitating when severe. The mechanisms of pruritus are not particularly well understood and are compounded by the subjective nature of the process itself. Pruritus occurs with a host of dermatological conditions, but can also be a marker of systemic disease. Dermatologists and primary care physicians must be aware of the varied causes of itching.
""Pruritis - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pruritis pipeline landscape is provided which includes the disease overview and Pruritis treatment guidelines. The assessment part of the report embraces, in depth Pruritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pruritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Pruritis R&D. The therapies under development are focused on novel approaches to treat/improve Pruritis.
Pruritis Drugs
- Linerixibat: GlaxoSmithKline
Further product details are provided in the report……..
Pruritis: Therapeutic Assessment
This segment of the report provides insights about the Pruritis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Pruritis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intranasal
- Intrathecal
- Intravenous
- Oral
- Oral/Intravenous
- Parenteral
- Subcutaneous
- Subcutaneous/Intramuscular
- Transdermal
- Molecule Type
- Antisense oligonucleotide
- Gene therapy
- Hormones
- Neuropeptides
- Oligonucleotides
- Small Molecule
- Triglyceride
- Product Type
Pruritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pruritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pruritis drugs.
Pruritis Report Insights
- Pruritis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pruritis drugs?
- How many Pruritis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pruritis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pruritis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pruritis and their status?
- What are the key designations that have been granted to the emerging drugs?
- GlaxoSmithKline
- Chugai Pharmaceutical
- Regeneron/Sanofi
- DiverDrugs
- Atridia
- Asana BioSciences
- Vanda Pharmaceuticals
- Pfizer
- Trevi Therapeutics
- AbbVie
- Lumosa Therapeutics
- Luye Pharma Group
- Linerixibat
- Nemolizumab
- Dupilumab
- Parentide
- SHR 0410
- ASN 008
- Tradipitant
- Abrocitinib
- Nalbuphine extended release
- Onabotulinum toxin A
- LT 5001
- BA 2101
Key Players
Table of Contents
120 Pages
- Introduction
- Executive Summary
- Pruritis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Pruritis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Linerixibat: GlaxoSmithKline
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- Onabotulinum toxin A: AbbVie
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- SHR 0410: Atridia
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- BA 2101: Luye Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Pruritis Key Companies
- Pruritis Key Products
- Pruritis- Unmet Needs
- Pruritis- Market Drivers and Barriers
- Pruritis- Future Perspectives and Conclusion
- Pruritis Analyst Views
- Pruritis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
